Valuation: TAUNS Laboratories,Inc.

Market Cap 49.83B 318M 276M 258M 237M 446M 30.29B 454M 3.04B 1.19B 15.11B 1.19B 1.17B P/E 2025
8.67x
P/E 2026 * 9.39x
Enterprise Value 56.65B 361M 314M 293M 269M 508M 34.44B 516M 3.46B 1.35B 17.18B 1.36B 1.33B EV / Sales 2025
3.23x
EV / Sales 2026 * 3.92x
Free-Float
29.89%
Yield 2025
5.2%
Yield 2026 * 7.55%
1 day-0.21%
1 week-1.48%
Current month-1.48%
1 month-0.21%
3 months-8.09%
6 months-13.70%
Current year-8.45%
1 week 465
Extreme 465
482
1 month 464
Extreme 464
493
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 2014-04-30
Director of Finance/CFO 66 2018-10-31
Corporate Officer/Principal 39 2022-06-30
Director TitleAgeSince
Director/Board Member 51 2014-04-30
Director/Board Member 66 2020-08-31
Director/Board Member 53 2016-03-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-1.48%-11.74% - 317M
-1.95%+9.18%+283.46%+346.90% 21.74B
+4.56%+2.19%-41.78%-24.25% 9.36B
+1.56%-6.33%+43.39%+38.50% 6.49B
-0.55%+2.37%+259.40%-19.63% 6B
+0.17%+2.09%-11.61%-15.66% 5.57B
+4.15%+4.41%-41.80% - 4.43B
0.00%+12.05%-12.81%-23.15% 4.38B
-5.57%-10.70%+65.05%+81.04% 4.25B
+3.20%+7.08%-14.64%-35.31% 2.8B
Average +0.54%+2.32%+51.69%+43.56% 6.53B
Weighted average by Cap. +0.18%+3.88%+115.34%+123.85%

Financials

2025 2026 *
Net sales 19.06B 122M 106M 98.65M 90.56M 171M 11.59B 174M 1.16B 456M 5.78B 457M 447M 14.76B 94.12M 81.8M 76.37M 70.11M 132M 8.97B 134M 900M 353M 4.47B 354M 346M
Net income 6.5B 41.46M 36.03M 33.64M 30.88M 58.23M 3.95B 59.24M 397M 155M 1.97B 156M 152M 5.2B 33.18M 28.83M 26.92M 24.71M 46.6M 3.16B 47.41M 317M 124M 1.58B 125M 122M
Net Debt 6.83B 43.56M 37.86M 35.34M 32.45M 61.18M 4.15B 62.25M 417M 163M 2.07B 164M 160M 7.99B 50.99M 44.31M 41.37M 37.98M 71.62M 4.86B 72.86M 488M 191M 2.42B 192M 187M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
26-08-03 ¥466.00 -0.21% 103,300
26-08-03 ¥467.00 -1.27% 508,200
26-07-31 ¥473.00 -0.63% 252,800
26-07-30 ¥476.00 -1.24% 221,800
26-07-29 ¥482.00 +1.90% 429,400
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
467.00JPY
Average target price
420.00JPY
Spread / Average Target
-10.06%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock